Streetbeat News

Stock Prices

LINC

Lincoln Educational Services has updated its FY24 revenue guidance to a range of $423M-$430M, compared to the previous estimate of $418M-$428M. The consensus estimate was $423.57M.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:12 pm

GCMG

GCM Grosvenor (NASDAQ:GCMG) reported Q2 2024 adjusted EPS of $0.15, beating the $0.14 estimate. Sales were $116.954M, surpassing the $113.300M estimate and showing an 8.68% increase from last year's $107.613M.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:10 pm

STER

Sterling Check reported its Q2 2024 financial results, with adjusted EPS of $0.23 missing the $0.28 estimate, but sales of $200.528 million beating the $197.624 million estimate.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:10 pm

GUTS

Fractyl Health, Inc. (NASDAQ:GUTS) announced new clinical results from its German Real-World Registry, showing significant weight loss and blood sugar reduction in patients with obesity and Type 2 Diabetes after a single Revita endoscopic procedure. The results indicate a median weight loss of nearly 13% and a substantial decrease in HbA1c levels over 12 months.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:08 pm

RVLV

VFC

As of August 8, 2024, VF Corp (NYSE:VFC) and Revolve Group Inc (NYSE:RVLV) are considered overbought with RSI values above 70. Despite reporting better-than-expected financial results, their recent stock price surges and high RSI values suggest potential short-term price corrections.

Portfolio Pulse from Avi Kapoor

August 08, 2024 | 12:08 pm

GSAT

Globalstar has raised its FY24 revenue guidance from $225M-$250M to $235M-$250M, compared to the $237.530M estimate.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:06 pm

CHPT

ChargePoint (NYSE:CHPT) announced the ChargePoint® Omni Port, an adaptable EV charging solution that allows any EV to charge in any parking space without needing an additional cable. This new feature is available at no extra cost.

Portfolio Pulse from charles@benzinga.com

August 08, 2024 | 12:06 pm

EVAX

Evaxion Biotech A/S (NASDAQ:EVAX) will present one-year clinical efficacy data from its Phase 2 study on its lead cancer vaccine candidate, EVX-01, at the ESMO Congress 2024. The vaccine is being tested in patients with advanced melanoma.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:06 pm

CARM

Carisma Therapeutics announced that its cash and equivalents are expected to be sufficient to sustain its planned operations into the third quarter of 2025.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:05 pm

XPEL

XPEL (NASDAQ:XPEL) reported Q2 2024 adjusted EPS of $0.54, beating the estimate of $0.46 by 17.39%. Sales were $109.90M, surpassing the $105.68M estimate and showing a 7.50% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:04 pm